Doping Bulky Fluorinated Organic Anion to Construct Highly Efficient Anion‐π <sup>+</sup> Type Photosensitizers for Cancer Phototheranostics — Lingxiu Liu (2025) | RDL Network
Doping Bulky Fluorinated Organic Anion to Construct Highly Efficient Anion‐π <sup>+</sup> Type Photosensitizers for Cancer Phototheranostics
Article 2025 en
Authors
LL
Lingxiu Liu
JG
Jianye Gong
XW
Xue Wang
Abstract
1 min read
Abstract Anion‐π + type photosensitizers with aggregation‐induced emission (AIE) feature have demonstrated promising potential in photodynamic therapy (PDT) against cancer. However, previous reports mainly focused on modifying the π + core but often overlooked the crucial role of anions. Herein, we present a facile strategy to modulate the fluorescence intensity and cellular uptake of anion‐π + type AIE photosensitizers by doping bulky fluorinated organic anions into nanoparticles (NPs). Anion‐π + type AIE photosensitizer DPBCF‐Br with different ratios of bulky anions (TB or FTB) were encapsulated into DSPE‐PEG 2000 to obtain NPs (named DF‐TB X or DF‐FTB X , X denotes the molar ratios of TB or FTB to DPBCF‐Br). Expectedly, as the doping molar ratios increased, a progressive enhancement in fluorescence intensity of the obtained NPs was observed. This can be ascribed to the steric effect of bulky organic anions and the formation of a hydrophobic environment within the NPs. Interestingly, the optimal cellular uptake was achieved at X = 8 in DF‐TB 8 and DF‐FTB 8 , resulting from the balance between lipophilicity and electronegativity. Ultimately, DF‐FTB 8 demonstrated outstanding cellular imaging capabilities and high intracellular reactive oxygen species generation, achieving efficient cancer phototheranostics. This facile bulky anion doping strategy will pave a new way for the construction of robust anion‐π + type photosensitizers.
Shiping Yang, Hongchi Yu, Junkai Liu, Lunjie Ma, Zhe Hou, Jia Ma, Michael Z. Miao, Ryan T. K. Kwok, Jianwei Sun, Herman H. Y. Sung, Ian D. Williams, Jacky W. Y. Lam, Xiaoheng Liu, Ben Zhong Tang
Discussion(0)
No comments yet. Be the first to comment.